TWI332833B - New pharmaceutical compositions based on anticholinergics and pde-iv inhibitors - Google Patents

New pharmaceutical compositions based on anticholinergics and pde-iv inhibitors Download PDF

Info

Publication number
TWI332833B
TWI332833B TW091104144A TW91104144A TWI332833B TW I332833 B TWI332833 B TW I332833B TW 091104144 A TW091104144 A TW 091104144A TW 91104144 A TW91104144 A TW 91104144A TW I332833 B TWI332833 B TW I332833B
Authority
TW
Taiwan
Prior art keywords
micrograms
present
inhalable powder
powder composition
salt
Prior art date
Application number
TW091104144A
Other languages
English (en)
Chinese (zh)
Inventor
Pairet Michel
John Montague Meade Christopher
P Pieper Michael
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of TWI332833B publication Critical patent/TWI332833B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW091104144A 2001-03-07 2002-03-06 New pharmaceutical compositions based on anticholinergics and pde-iv inhibitors TWI332833B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10110772A DE10110772A1 (de) 2001-03-07 2001-03-07 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren

Publications (1)

Publication Number Publication Date
TWI332833B true TWI332833B (en) 2010-11-11

Family

ID=7676493

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091104144A TWI332833B (en) 2001-03-07 2002-03-06 New pharmaceutical compositions based on anticholinergics and pde-iv inhibitors

Country Status (18)

Country Link
EP (1) EP1372649B1 (enExample)
JP (1) JP2004521134A (enExample)
KR (1) KR20030081501A (enExample)
CN (1) CN1649588A (enExample)
AR (1) AR034213A1 (enExample)
AU (1) AU2002257587B2 (enExample)
BR (1) BR0207883A (enExample)
CA (1) CA2439763C (enExample)
CZ (1) CZ20032635A3 (enExample)
DE (1) DE10110772A1 (enExample)
EA (1) EA009989B1 (enExample)
HU (1) HUP0400782A3 (enExample)
IL (2) IL157326A0 (enExample)
MX (1) MXPA03008045A (enExample)
NZ (1) NZ528621A (enExample)
PL (1) PL363078A1 (enExample)
TW (1) TWI332833B (enExample)
WO (1) WO2002069945A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2276942T3 (es) * 2001-05-25 2007-07-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Combinacion de un inhibidor de pde4 y tiotropio o un derivado del mismo para tratar vias respiratorias obstructivas y otras enfermedades inflamatorias.
GB0118373D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US20030235538A1 (en) 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
DE10230769A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
WO2004084894A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases
CA2519682A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
ATE384529T1 (de) * 2003-03-28 2008-02-15 Nycomed Gmbh Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
EP1651208A1 (en) * 2003-07-28 2006-05-03 Boehringer Ingelheim International GmbH Medicaments comprising pde iv inhibitors and a novel anticholinergic and their use for treating respiratory disorders
US7071333B2 (en) 2003-07-30 2006-07-04 Bristol-Myers Squibb Company Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
EP1504756A1 (en) * 2003-08-06 2005-02-09 Kyowa Hakko Kogyo Co., Ltd Medicament compositions comprising a heterocyclic compound and an anticholinergic
EP1706118A1 (en) * 2004-01-09 2006-10-04 Boehringer Ingelheim International GmbH New pharmaceutical compositions based on a scopineester and nicotinamide derivatives
RU2006132043A (ru) * 2004-02-06 2008-03-20 МЕДА Фарма ГмбХ унд Ко.КГ (DE) Комбинация и фармацевтический препарат для лечения ринита
PL1713471T3 (pl) * 2004-02-06 2012-06-29 Meda Pharma Gmbh & Co Kg Kombinacja środków antycholinergicznych i inhibitorów fosfodiesterazy typu 4 do leczenia chorób oddechowych
AU2005210085B2 (en) 2004-02-06 2010-06-24 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD
EP1720543A1 (en) * 2004-02-27 2006-11-15 Altana Pharma AG Roflumilast and glycopryrronium combination
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
MX2007011273A (es) 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
WO2007071313A2 (en) 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
PT2046787E (pt) 2006-08-01 2011-06-15 Glaxo Group Ltd Compostos de pirazolo[3,4-b]piridina e sua utilização como inibidores de pde4
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
MX2011007499A (es) 2009-01-13 2011-08-04 Glaxo Group Ltd Derivados de pirimidin-carboxamida como inhibidores de la cinasa syk.
WO2012025474A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Indazole compounds
WO2012025473A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Cc.chemokine receptor 4 antagonists
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN102670607A (zh) * 2012-05-28 2012-09-19 海南卫康制药(潜山)有限公司 复方盐酸氨溴索组合物及其制备方法
SI2968313T1 (en) 2013-03-15 2018-05-31 Verona Pharma Plc Combination of medicines
CN105358077A (zh) * 2013-05-31 2016-02-24 因西坡设备公司 髋臼扩孔钻组件

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
MY134008A (en) * 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
AU2700301A (en) * 2000-01-31 2001-08-14 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
DE60125026T2 (de) * 2000-03-23 2007-06-28 Takeda Pharmaceutical Co. Ltd. Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito

Also Published As

Publication number Publication date
HUP0400782A3 (en) 2012-09-28
EP1372649A2 (de) 2004-01-02
JP2004521134A (ja) 2004-07-15
KR20030081501A (ko) 2003-10-17
NZ528621A (en) 2005-04-29
PL363078A1 (en) 2004-11-15
CA2439763A1 (en) 2002-09-12
CZ20032635A3 (cs) 2004-09-15
IL157326A0 (en) 2004-02-19
WO2002069945A3 (de) 2003-01-30
DE10110772A1 (de) 2002-09-12
CA2439763C (en) 2012-10-16
WO2002069945A2 (de) 2002-09-12
AR034213A1 (es) 2004-02-04
HUP0400782A2 (hu) 2004-07-28
EP1372649B1 (de) 2012-07-25
IL157326A (en) 2011-12-29
BR0207883A (pt) 2004-07-27
EA009989B1 (ru) 2008-04-28
AU2002257587B2 (en) 2007-05-10
EA200300929A1 (ru) 2004-04-29
CN1649588A (zh) 2005-08-03
MXPA03008045A (es) 2003-12-04

Similar Documents

Publication Publication Date Title
CA2439763C (en) Pharmaceutical compositions based on anticholinergics and pde-iv inhibitors
JP4537652B2 (ja) 抗コリン作用薬及びシクレソニドをベースとする新規薬剤組成物
US20040024007A1 (en) Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
JP4282594B2 (ja) チオトロピウム塩及びサルメテロール塩に基づく新規医薬組成物
US6608054B2 (en) Pharmaceutical compositions based on anticholinergics and endothelin antagonists
CA2733294C (en) Pharmaceutical combination of a tiotropium salt and ciclesonide
US20040058950A1 (en) Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
JP2004528305A (ja) 炎症性疾患を治療するための化合物
US20040192675A1 (en) Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
WO2004024156A1 (en) Tiotropium salts for reducing respiratory mortality rate
US20040161386A1 (en) Pharmaceutical compositions based on anticholinergic and dopamine agonists
TW200406209A (en) Medicament combinations comprising heterocyclic compounds and a novel anticholinergic
CA2629074A1 (en) Aerosol formulation for inhalation containing an anticholinergic agent
TW200303866A (en) New medicament compositions comprising besides anticholinergics heterocyclic compounds
AU2002221738B2 (en) Inhalative solution formulation containing a tiotropium salt
CA2492026A1 (en) New pharmaceutical compositions based on new anticholinergics and pde-iv inhibitors
JP2004512379A (ja) 新規医薬組成物
ZA200306221B (en) Novel medicament compositions on the basis of anti-cholinergics and PDE IV inhibitors.
JP2004525920A (ja) 抗コリン作動薬及びエンドテリンアンタゴニストを主成分とする新規薬剤組成物
CA2430592C (en) New pharmaceutical compositions based on anticholinergics and dopamine agonists
JP4850415B2 (ja) 吸入用チオトロピウム含有医薬品組成物
TW200307550A (en) Medicaments comprising BETAMIMETICS and a novel anticholinergic
CA2614631C (en) Pharmaceutical compositions based on anticholinergics and corticosteroids in the form of an inhalable solution or suspension